What to Watch as Pasqal's SPAC Merger Heads Toward Close
Pasqal, a French neutral-atom quantum computing company, is going public through a SPAC merger with Bleichroeder Acquisition France Merger Sub 2. The setup offers real commercial traction and a large financing package, but shareholders should watch redemption risk, dilution, and whether the deal closes with the expected cash intact.
Pasqal, a French neutral-atom quantum computing company, is going public through a SPAC merger with Bleichroeder Acquisition France Merger Sub 2. The setup offers real commercial traction and a large financing package, but shareholders should watch redemption risk, dilution, and whether the deal closes with the expected cash intact.
Deal at a Glance
SPAC partner: Bleichroeder Acquisition France Merger Sub 2
SPAC ticker (trades now): BBCQ
Implied valuation: $2.0B pre-money equity value
Expected close: H2 2026
Est. first trading date: late Q3 to Q4 2026
Deal status: Announced
Source filing: SEC 425 (2026-07-10)
Company Overview
Pasqal is a neutral-atom quantum computing company headquartered in France. Its core product is quantum processing units, or QPUs, built on neutral atoms, and it also offers a cloud access layer plus software that helps customers combine quantum and classical computing. Pasqal says it has 10 commercial QPUs total, with 7 installed and 3 in production, more than 40 clients and partners, and 25+ identified industrial use cases. The company was founded by Alain Aspect and Antoine Browaeys and says it has a global team of more than 275 employees.
Pasqal is positioning itself as a commercial quantum platform rather than a pure research story. It says it has demonstrated more than 1,000 trapped atoms and is targeting 10,000+ physical qubits per QPU and 200+ logical qubits by end-2029. The company’s materials frame the market as early-stage and globally competitive, with use cases in materials science, catalysis, corrosion, memory materials, and HPC integration. TAM was not disclosed in the materials reviewed, so the investment case here is about execution and commercialization rather than a defined market-size slide.
The SPAC Deal
Pasqal is merging with Bleichroeder Acquisition France Merger Sub 2, the SPAC vehicle tied to Bleichroeder Acquisition Corp. II. The deal values Pasqal at a $2.0 billion pre-money equity value. In the June 2026 investor presentation, Pasqal shows a pro forma equity value of $2,643.7 million and a pro forma enterprise value of $1,998.5 million, based on an assumed $10.00 share price and 264.4 million pro forma shares outstanding.
The trust account was disclosed at $291.4 million cash-in-trust as of May 31, 2026, inclusive of deferred underwriting fees of up to $12.25 million. The deck says the transaction’s $645.2 million cash to balance sheet assumes no redemptions, which is the key SPAC risk: if a large number of public shares are redeemed, cash proceeds fall and ownership shifts. Pasqal and Bleichroeder also disclosed a $250 million committed convertible financing to purchase $312.5 million aggregate principal amount of senior unsecured convertible bonds and investment warrants. The March 4 press release said the deal is expected to provide about $500 million of gross proceeds, assuming no redemptions and closing of the convertible financing.
Dilution is another item to watch. The deck’s illustrative pro forma ownership shows Existing Pasqal shareholders at 76%, Bleichroeder shareholders at 11%, Convertible investors at 10%, and the Bleichroeder sponsor at 3%. The company also warns that those figures do not reflect other dilution sources, including warrants and share-based compensation. The SPAC’s public warrants trade as BBCQW and its units as BBCQU before separation, confirming warrant overhang at the shell level. The current SPAC ticker is BBCQ, and the combined company is expected to trade as Pasqal Holding SA on Nasdaq, but the post-merger ticker has not been disclosed. The deal is announced and filed, not closed yet, and Bleichroeder said closing is expected in the second half of 2026 subject to shareholder, regulatory, and Nasdaq approvals. Based on that language, the estimated first-trading window is late Q3 to Q4 2026.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The SPAC route gives Pasqal a faster path to public markets and a financing package tied to the merger process. It also lets the company present projections and a long-term commercialization roadmap to investors, which is especially relevant for a pre-scale quantum business where the market is still valuing future platform potential more than near-term earnings power.
The use of proceeds is straightforward: strengthen the balance sheet, fund commercialization, and support the buildout of a platform that Pasqal says is already serving commercial customers. The committed convertible financing is a major part of that story because it adds capital beyond the SPAC trust, but it also comes with its own dilution and structure considerations. In other words, the SPAC structure helps Pasqal raise money and market the story now, but shareholders should watch how much of the headline cash survives redemptions and how much dilution comes with the financing stack.
Financial Highlights
Pasqal disclosed €16.5 million of 2025 commercial revenue versus €14.3 million in 2024, which implies roughly 15% year-over-year growth. The company also said it had approximately 100% revenue growth in 2025 on an unaudited basis in its March 2026 press release, but the later investor deck’s revenue figures are the more concrete numbers to anchor on. The key takeaway is that Pasqal is generating commercial revenue today, but it is still early in the scale-up phase.
On profitability and cash flow, the company is still loss-making. The proxy says Pasqal has incurred net losses since inception and had negative cash flows from operations. It disclosed €35.1 million of free cash flow burn in FY2025, down from €50.0 million in FY2024, while total operating expenses rose to €76.1 million in 2025 from €61.3 million in 2024. The deck’s bridge graphics show $139.8 million of Pasqal existing cash, $291.4 million of SPAC trust, and $250.0 million of convertible financing feeding the pro forma cash picture. The materials also show cash on hand of $250.0 million and $255.4 million in the deck’s bridge graphics, but the main point is that the deal is being sold as a well-capitalized launch into the public market, not as a profitable business today.
Risk Factors
The biggest de-SPAC-specific risk is redemptions. The transaction’s cash-to-balance-sheet figure assumes no redemptions, and the proxy materials say that if a significant number of Bleichroeder shares are redeemed, the combined company’s ownership and cash proceeds would be reduced. That matters because the trust is only one part of the financing stack, and the headline valuation can look very different if the SPAC cash leaves at the vote.
Dilution is the other major issue. Public holders face sponsor promote, warrants, and share-based compensation, and the deck explicitly warns that the ownership percentages do not reflect all of those potential dilution sources. Beyond the deal mechanics, Pasqal still faces execution risk as a technical company scaling commercialization, competition in a globally competitive quantum market, and industry immaturity if adoption takes longer than expected. The transaction also remains subject to shareholder, regulatory, and Nasdaq approvals, so there is still deal-break risk before the combined company starts trading.
Comparable Public Companies
The cleanest public comps in the quantum computing group are IonQ (IONQ), Rigetti Computing (RGTI), D-Wave Quantum (QBTS), Quantum Computing Inc. (QUBT), and Arqit Quantum (ARQQ). Pasqal’s own materials use this peer set to frame the market, and the broader read-through is that public quantum names still trade on long-duration optionality rather than conventional near-term earnings metrics.
That means the comp set generally carries very elevated revenue multiples relative to traditional software or industrial names, even though current revenues are still small. Pasqal is trying to stand out by showing commercial QPUs, installed systems, and revenue today, which makes it more of a commercialization story than a pure research bet. For cross-linking, the cited peer tickers are IONQ, RGTI, QBTS, QUBT, and ARQQ.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
This is a real commercial quantum story, not just a concept slide deck. Pasqal has revenue, installed QPUs, a committed convertible financing package, and a stated path toward larger-scale quantum systems by 2029. That is why the deal matters now: it gives public-market investors a way to price one of the more advanced neutral-atom platforms before the category is fully mature.
What shareholders should watch next is simple: redemption levels, final financing terms, and whether the cash actually lands near the no-redemption headline. The setup favors investors who want exposure to quantum commercialization, but the deal still carries the usual de-SPAC tradeoffs: dilution, trust leakage, and execution risk. If the merger closes in the expected second half of 2026 window, the first trading window is likely late Q3 to Q4 2026 on Nasdaq under the Pasqal Holding SA name, with the final ticker still undisclosed.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
